Allergan and Molecular Partners have announced the release of two positive clinical trials of a new treatment for wet age-related macular degeneration (wAMD). The trials, named SEQUOIA and CEDAR, demonstrated that the biological drug Abicipar is equal to Genentech’s Lucentis (ranibizumab), with the added benefit that Abicipar treatments are effective at up to 12-week dosages. [Read More]
Category: Latest News
Suffering From Dry Eye?
Age-related macular degeneration (AMD) is the most common cause of visual impairment in people over age 60. Because it affects millions of senior adults, it deserves a great deal of attention. Another common condition also deserving of consideration is dry eye. Dry eye often accompanies AMD, but only because it most commonly affects the same [Read More]
Protect Your Eyes From Fireworks Injuries
Prevent Blindness wants all Americans to know that 14% of all injuries from fireworks are to the eyes, and that contusions, lacerations, and foreign bodies in the eyes occurred more frequently than burns to other parts of the body. Here are more important statistics from the U.S. Consumer Product Safety Commission: Fireworks devices were involved [Read More]
Summary of Research and Development — 2018
Transcript of a presentation to the International Low Vision Support Group June 2018 Dan Roberts, Director Select this link for audio-visual format INTRODUCTION This is our 13th annual summary of leading research and developments occuring during the past 12 months in the fields of blindness and low vision. Sources for further information will appear beneath [Read More]
Every Patient Can Be an Advocate
by Dan Roberts What do these six famous people have in common? They are all different in many ways, but they each possess at least one characteristic which sets them apart. They have a strong sense of empathy, making it impossible for them to remain silent in the face of adversity. They all believe in [Read More]